[go: up one dir, main page]

WO2014203267A3 - Method for isolation, purification and industrial scale expansion of human adipose tissue derived mesenchymal stem cells - Google Patents

Method for isolation, purification and industrial scale expansion of human adipose tissue derived mesenchymal stem cells Download PDF

Info

Publication number
WO2014203267A3
WO2014203267A3 PCT/IN2013/000582 IN2013000582W WO2014203267A3 WO 2014203267 A3 WO2014203267 A3 WO 2014203267A3 IN 2013000582 W IN2013000582 W IN 2013000582W WO 2014203267 A3 WO2014203267 A3 WO 2014203267A3
Authority
WO
WIPO (PCT)
Prior art keywords
isolation
purification
stem cells
mesenchymal stem
adipose tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2013/000582
Other languages
French (fr)
Other versions
WO2014203267A2 (en
Inventor
Satish Mahadeorao Totey
Lyle Carl FONSECA
Manoj Kumar C REDDY
Shashank GOWDA
Aarya HARI
Basavaraj CHOUGULE
Minita SODHI
Sneha Deepak LAGHATE
Nicole Rachel KOSHY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KASIAK RESEARCH PVT Ltd
Original Assignee
KASIAK RESEARCH PVT Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KASIAK RESEARCH PVT Ltd filed Critical KASIAK RESEARCH PVT Ltd
Publication of WO2014203267A2 publication Critical patent/WO2014203267A2/en
Publication of WO2014203267A3 publication Critical patent/WO2014203267A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention relates to a method for isolation, purification and industrial scale expansion of human adipose tissue derived mesenchymal stem cells (MSCs). The invention also relates to a method for treating and a therapeutic product for treating type-1 diabetes mellitus, critical limb ischemia, multiple sclerosis, Duchenne muscular dystrophy, rheumatoid arthritis, cerebral stroke, type-II diabetes, idiopathic pulmonary fibrosis, dilated cardiomyopathy, and osteoarthritis comprising MSCs.
PCT/IN2013/000582 2013-06-17 2013-09-26 Method for isolation, purification and industrial scale expansion of human adipose tissue derived mesenchymal stem cells Ceased WO2014203267A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2045/MUM/2013 2013-06-17
IN2045MU2013 IN2013MU02045A (en) 2013-06-17 2013-09-26

Publications (2)

Publication Number Publication Date
WO2014203267A2 WO2014203267A2 (en) 2014-12-24
WO2014203267A3 true WO2014203267A3 (en) 2015-03-26

Family

ID=52105422

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2013/000582 Ceased WO2014203267A2 (en) 2013-06-17 2013-09-26 Method for isolation, purification and industrial scale expansion of human adipose tissue derived mesenchymal stem cells

Country Status (2)

Country Link
IN (1) IN2013MU02045A (en)
WO (1) WO2014203267A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR20150100378A (en) * 2015-08-25 2017-04-10 Βαλερι-Σεσιλ-Αννα Παντελη Αγγελου Method for the isolation of mesenchymal stem cells from adipose tissues
EP3342858B1 (en) 2015-08-28 2023-10-04 Rohto Pharmaceutical Co., Ltd. Ror1-positive mesenchymal stem cells and method for preparing same, pharmaceutical composition containing ror1-positive mesenchymal stem cells and method for preparing same, and method for preventing or treating diseases by using ror1-positive mesenchymal stem cells
WO2017068140A1 (en) 2015-10-23 2017-04-27 Rigshospitalet Stem cell therapy based on adipose-derived stem cells
CN118406643A (en) * 2016-11-11 2024-07-30 美商生命科学有限公司 Method for realizing cell immunity and humoral immunity by using human mesenchymal stem cells
EP3583945A4 (en) * 2017-02-15 2020-11-18 Rohto Pharmaceutical Co., Ltd. AGENTS FOR TREATMENT OF LUNG FIBROSIS, PTPRR EXPRESSION PROMOTING AGENT AND KIT FOR TREATMENT OF LUNG FIBROSIS
US20200069740A1 (en) * 2017-03-08 2020-03-05 Rohto Pharmaceutical Co., Ltd. Ror1-positive mesenchymal stem cell-containing pharmaceutical composition for preventing or treating disease associated with fibrosis, method for preparing same, and method for preventing or treating disease associated with fibrosis using ror1-positive mesenchymal stem cells
US20210047621A1 (en) 2018-03-12 2021-02-18 Universidade Do Porto Compositions for use in the treatment of musculoskeletal conditions and methods for producing the same leveraging the synergistic activity of two different types of mesenchymal stromal/stem cells
EP3923960A1 (en) 2019-02-15 2021-12-22 Rigshospitalet, Copenhagen University Hospital Stem cell therapy for lacrimal gland dysfunction
WO2020165405A1 (en) 2019-02-15 2020-08-20 Rigshospitalet Stem cell therapy for patients with salivary gland dysfunction
CN111514164A (en) * 2020-04-30 2020-08-11 深圳市合一康生物科技股份有限公司 Adipose-derived mesenchymal stem cells for treating lung diseases and preparation method thereof
EP3909593A1 (en) 2020-05-15 2021-11-17 Rigshospitalet Stem cells for treating skin lesions
US20240003893A1 (en) * 2020-11-30 2024-01-04 Cz Biohub Sf, Llc Reconstitution of a split-halotag via orthogonal tag-binding domains
CN112646030B (en) * 2021-01-11 2021-11-30 内蒙古创润生物科技有限公司 Application of pharmaceutical composition containing mesenchymal stem cell exosomes in treating diseases
HU231475B1 (en) * 2021-04-01 2024-02-28 Cellfactory Korlátolt Felelősségű Társaság Process for the production of a composition for the treatment of an individual suffering from osteoarthritis
US20240425815A1 (en) * 2021-09-23 2024-12-26 Aarhus Universitet Ready-to-use stem cell therapeutic

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070274965A1 (en) * 2006-05-17 2007-11-29 Cognate Therapeutics, Inc. Isolation and purification of hematopoietic stem cells from post-liposuction lipoaspirates
US20110229965A1 (en) * 2009-11-27 2011-09-22 Rakhi Pal Methods of Preparing Mesenchymal Stem Cells, Compositions and Kit Thereof
US20110244566A1 (en) * 2010-02-01 2011-10-06 Joseph Wu Enhanced efficiency of induced pluripotent stem cell generation
US20120244130A1 (en) * 2009-10-06 2012-09-27 National University Corporation Nagoya University Cell preparation for erectile dysfunction or sensory disorders of the lower urinary tract containing adipose tissue derived mesenchymal stem cells
US20120251489A1 (en) * 2009-12-09 2012-10-04 Maria Beatriz Herrera Sanchez Adult stem cell derived conditioned medium and/or adult stem cells for use in the therapeutic treatment of a tumor disease
US20130129688A1 (en) * 2011-11-09 2013-05-23 Allocure, Inc. Assay for the Prediction of Therapeutic Effectiveness or Potency of Mesenchymal Stem Cells, and Methods of Using Same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070274965A1 (en) * 2006-05-17 2007-11-29 Cognate Therapeutics, Inc. Isolation and purification of hematopoietic stem cells from post-liposuction lipoaspirates
US20120244130A1 (en) * 2009-10-06 2012-09-27 National University Corporation Nagoya University Cell preparation for erectile dysfunction or sensory disorders of the lower urinary tract containing adipose tissue derived mesenchymal stem cells
US20110229965A1 (en) * 2009-11-27 2011-09-22 Rakhi Pal Methods of Preparing Mesenchymal Stem Cells, Compositions and Kit Thereof
US20120251489A1 (en) * 2009-12-09 2012-10-04 Maria Beatriz Herrera Sanchez Adult stem cell derived conditioned medium and/or adult stem cells for use in the therapeutic treatment of a tumor disease
US20110244566A1 (en) * 2010-02-01 2011-10-06 Joseph Wu Enhanced efficiency of induced pluripotent stem cell generation
US20130129688A1 (en) * 2011-11-09 2013-05-23 Allocure, Inc. Assay for the Prediction of Therapeutic Effectiveness or Potency of Mesenchymal Stem Cells, and Methods of Using Same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CARVALHO ET AL.: "Isolation and immunophenotypic characterization of mesenchymal stem cells derived from equine species adipose tissue.", VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, vol. 132.2, 2009, pages 303 - 306 *
OEDAYRAJSINGH-VARMA, M. J. ET AL.: "Adipose tissue-derived mesenchymal stem cell yield and growth characteristics are affected by the tissue-harvesting procedure.", CYTOTHERAPY, vol. 8.2, 2006, pages 166 - 177 *

Also Published As

Publication number Publication date
WO2014203267A2 (en) 2014-12-24
IN2013MU02045A (en) 2015-06-05

Similar Documents

Publication Publication Date Title
WO2014203267A3 (en) Method for isolation, purification and industrial scale expansion of human adipose tissue derived mesenchymal stem cells
WO2014203269A3 (en) Method for isolation, purification and industrial scale expansion of canine adipose tissue derived mesenchymal stem cells
BR112018004377A2 (en) yeast strains for the expression and secretion of heterologous proteins at elevated temperatures
ECSP17039547A (en) NEW STANDARDS AND MEDICAL DEVICES FOR THE PREPARATION OF PLASMA RICH IN PLATES (PRP) OR BONE MARROW CONCENTRATE (BMC) ALONE OR COMBINED WITH HYALURONIC ACID
HK1257840A1 (en) Anti-pd-1 antibodies and methods of use thereof
EP3162894A3 (en) Methods for the manufacture of proteolytically processed polypeptides
MY186892A (en) Utilizing a multiphase reactor for the conversion of biomass to produce substituted furans
UA109575C2 (en) METHOD OF THERMAL STERILIZATION OF MEDICAL CONTAINER
PL2665826T3 (en) Process for the fermentative production of sulphur-containing amino acids
MX2015015188A (en) Novel cloning, expression & purification method for the preparation of ranibizumab.
MY189932A (en) Recombinant microorganism for improved production of alanine
PH12016501777A1 (en) Novel lactobacillus paracasei strain
ZA201803510B (en) Process for the production of 2,5-furandicarboxylic acid (fdca)
BR112015030655A2 (en) Xylanase Variants and Polynucleotides Encoding Them
EA201691754A1 (en) RECOMBINANT MICROORGANISM, EXPRESSING ANALOG AVERMECTIN, AND ITS APPLICATION
NZ706877A (en) Hop extract oxidation-reaction product, preparing method thereof and use thereof
MY174468A (en) Bio-based arcylic acid and its derivatives
HK1222325A1 (en) High potency pancreatin pharmaceutical compositions
MY187692A (en) Distillation system for reducing energy consumption by thermal coupling
FI20135333A7 (en) Production of acid(s) and alcohol from sugars using yeast
CO6430457A2 (en) PROCESS FOR THE PREPARATION OF AMIDAS OF CARBOXILIC ACID PIRAZOL
WO2014203268A3 (en) Method for isolation, purification and industrial scale expansion of equine adipose tissue derived mensenchymal stem cells
WO2015057836A3 (en) Bone anabolic parathyroid hormone and parathyroid hormone related-protein analogs
WO2015018507A3 (en) A novel process for the preparation of febuxostat
BR112012027144A2 (en) tomato derived thickening agent, process for preparing a tomato derived thickening agent, method for preparing a food product and tomato ketchup product obtainable by the process

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13887381

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13887381

Country of ref document: EP

Kind code of ref document: A2